

MUCOADHESIVE DRUG DELIVERY SYSTEMS: MECHANISTIC FOUNDATIONS, ADVANCED POLYMERS, PHARMACEUTICAL APPLICATIONS, AND TRANSLATIONAL PERSPECTIVES

¹*Mr. Yash Kishor Gangurde, ²Ms. Prachiti Sanjay Jagtap, ³Mrs. Smita Rajendra Rupvate

¹Student, Mahatma Gandhi Vidyamandir's Pharmacy College, Panchavati, Nashik, -03 Maharashtra.

²Student, Sir Dr. M.S. Gosavi College of Pharmaceutical Education and Research, Nashik, 03 Maharashtra.

³Senior Lecturer, METs Institute of D.Pharmacy Adgaon Nashik, Maharashtra.

Article Received on 15 July 2026,
Article Revised on 05 August 2026,
Article Published on 16 August 2026,

<https://doi.org/10.5281/zenodo.21989769>

*Corresponding Author

Mr. Yash Kishor Gangurde

Student, Mahatma Gandhi
Vidyamandir's Pharmacy College,
Panchavati, Nashik, -03 Maharashtra.



How to cite this Article: ¹*Mr. Yash Kishor Gangurde, ²Ms. Prachiti Sanjay Jagtap, ³Mrs. Smita Rajendra Rupvate. (2026). Mucoadhesive Drug Delivery Systems: Mechanistic Foundations, Advanced Polymers, Pharmaceutical Applications, And Translational Perspectives. World Journal of Pharmaceutical Research, 15(16), 1601-1619.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

The therapeutic efficacy of conventional drug delivery systems is frequently compromised by rapid mucociliary clearance, enzymatic degradation, and short residence times at biological absorption sites. Mucoadhesive drug delivery systems (MDDS) have emerged as a robust pharmaceutical strategy to overcome these physiological hurdles by utilizing the interfacial forces between polymeric carriers and mucosal membranes. This review critically examines the biophysical and molecular basis of mucoadhesion, with a particular focus on the transition from classical theories—such as wetting, diffusion, and adsorption—to advanced covalent bonding mechanisms facilitated by second-generation polymers. The evolution of mucoadhesive materials, ranging from natural polysaccharides (chitosan, alginate) to sophisticated thiolated, catechol-functionalized, and stimuli-responsive smart hydrogels. A route-specific synthesis

is provided for route-wise applications, including buccal, nasal, ocular, gastrointestinal, and vaginal delivery, highlighting the impact of MDDS on bypassing first-pass metabolism and enhancing drug bioavailability. Particular emphasis is placed on recent technological

innovations (2020–2026), including 3D-printed mucoadhesive platforms and nanotechnology-driven strategies that balance mucoadhesion with mucus penetration. Finally, we address the current translational challenges, including the lack of standardized characterization methods and regulatory hurdles, and outline future perspectives for personalized mucosal therapy. Collectively, the evidence is synthesized to identify design principles, translational barriers, and research priorities for the next generation of localized and systemic transmucosal delivery systems.

KEYWORDS: Mucoadhesion; Thiolated polymers; Mucosal drug delivery; Mucin interaction; Bioavailability enhancement; Nanotechnology; Smart hydrogels; Stimuli-responsive systems; 3D printing; Pharmaceutical translation.

1. INTRODUCTION

1.1 Conventional Drug Delivery Limitations

Conventional drug delivery systems, particularly oral and topical routes, face significant physiological hurdles that limit their therapeutic efficiency. In the gastrointestinal tract, the acidic environment of the stomach and the presence of digestive enzymes can degrade sensitive drugs, such as proteins and peptides.^{[1],[53]} Moreover, the rapid transit time through the absorption sites and the "wash-out" effect of biological fluids (saliva, tears, mucus) necessitate frequent dosing, which reduces patient compliance and leads to fluctuations in plasma drug concentrations.^{[5],[93]} Mucoadhesive drug delivery systems (MDDS) address these limitations by providing a prolonged residence time at the site of absorption, thereby enhancing drug bioavailability and therapeutic efficacy.^{[2],[87]}

1.2 Definition and Significance of Mucoadhesion

Mucoadhesion is defined as the state in which two materials, at least one of which is a biological mucosal surface, are held together for extended periods by interfacial forces. In the context of drug delivery, this interaction occurs between a polymeric carrier and the mucus layer or the epithelial surface.^{[1],[85]} The significance of mucoadhesion lies in its ability to:

- Increase the residence time of the dosage form at the site of absorption.
- Enhance the local concentration of the drug.
- Improve bioavailability by bypassing first-pass metabolism (e.g., buccal and nasal routes).
- Protect sensitive drugs from degradation in the GI tract.
- Reduce dosing frequency and improve patient compliance.^{[2],[87]}

1.3 Historical Development

Mucoadhesive drug delivery has evolved from simple viscous liquids used to treat oral lesions to sophisticated "smart" polymers that respond to physiological stimuli.^{[17],[88]} Early research focused on identifying natural gums and mucilages that could prolong contact with mucosal membranes.^{[7],[9]} However, the field has transitioned toward synthetic and semi-synthetic polymers with tailored molecular weights, charge densities, and functional groups to maximize adhesion and controlled drug release.^{[30],[38]} The timeline of mucoadhesion research reflects a shift from simple adhesion to multifunctional platforms.^{[45],[53]}

1.4 Objectives of the Review

This review aims to:

- Elucidate the biological and biophysical basis of mucoadhesion.
- Analyze the mechanical and molecular theories governing polymer-mucin interactions.
- Classify mucoadhesive polymers from first-generation to advanced stimuli-responsive systems.
- Examine pharmaceutical applications across various mucosal routes, including buccal, nasal, and ocular delivery.
- Critically evaluate recent technological innovations (2020-2026) and their translational status.

2. Literature Search Strategy / Review Methodology

A structured literature search was conducted to identify mechanistic, formulation, preclinical, clinical, and translational evidence relevant to mucoadhesive drug delivery. Literature published primarily between 2015 and 2026 was considered, while seminal earlier studies were retained where necessary to explain foundational concepts. PubMed, ScienceDirect, and SciSpace were used for literature identification. Because the present article is a narrative critical review rather than a registered systematic review, the search strategy was designed to provide broad thematic coverage rather than to support meta-analytic inference.

Keywords and Search Terms

Primary keywords included "mucoadhesion," "mucoadhesive drug delivery," "mucoadhesive polymers," "mucin interaction," "buccal delivery," "nasal drug delivery," "ocular mucoadhesion," "thiolated polymers," "thiomers," and "stimuli-responsive mucoadhesion".^[92]

Inclusion and Exclusion Criteria

Studies were prioritized when they provided mechanistic insight into polymer–mucin interactions, characterized mucoadhesive materials, reported *in vitro*, *ex vivo*, *in vivo*, or clinical evaluation, or addressed emerging technologies such as thiomers, bio-inspired adhesives, nanocarriers, stimuli-responsive systems, and additive manufacturing. Review articles were used to establish context and identify major themes, whereas original research was preferentially used to support quantitative or formulation-specific claims. Records lacking sufficient bibliographic information or direct relevance to pharmaceutical mucoadhesion were considered lower-priority evidence. Approximately 330 records were initially identified and screened during preparation of the review.

3. BIOLOGICAL BASIS

3.1 Mucus Structure and Composition

The mucosal membrane is the primary target for MDDS. It consists of an epithelial layer covered by a viscoelastic mucus layer. Mucus is a complex aqueous secretion containing 95% water, glycoproteins (mucins), lipids, inorganic salts, and enzymes.^{[62],[81],[96]} Mucins, the key functional components, are high-molecular-weight glycoproteins characterized by a protein core rich in serine, threonine, and proline, extensively glycosylated with carbohydrate side chains.^{[72],[86]}

3.2 Viscoelasticity and Barrier Functions

The viscoelastic properties of mucus are derived from the entanglement and cross-linking of mucin fibers, forming a three-dimensional gel network.^{[46],[83],[104]} This network acts as a selective physical barrier, trapping pathogens and foreign particles while allowing the diffusion of small molecules.^{[52],[63],[90]} The pH of the environment significantly influences mucus rheology; for instance, gastric mucus undergoes a sol-gel transition at low pH, which affects the adhesion of polymeric carriers.^{[46],[61],[81]}

3.3 Mucosal Membrane Barriers

Beyond the mucus layer, the underlying epithelium presents additional barriers, including tight junctions (paracellular route) and the lipophilic cell membrane (transcellular route).^{[11],[44]} Effective mucoadhesive systems must not only adhere to the mucus but often facilitate drug penetration through these epithelial barriers.^{[12],[69]}

4. Mechanisms and Theories of Mucoadhesion

Mucoadhesion is a multi-stage process involving an initial contact phase (wetting and swelling) followed by a consolidation phase (interpenetration and bonding).^{[6],[17],[18],[23]}

4.1 Wetting Theory

Applicable primarily to liquid and semi-solid systems, this theory emphasizes the ability of the mucoadhesive to spread over the mucosal surface. It is quantified by the contact angle and work of adhesion.^{[1],[4],[13],[21]}

4.2 Diffusion Theory

This theory proposes that the mucoadhesive polymer chains and mucin glycoproteins interpenetrate across the interface to form a semi-permanent adhesive bond.^{[1],[4],[13]} The depth of penetration depends on the diffusion coefficient, molecular weight, and chain flexibility of the polymer.^{[18],[60],[66]}

4.3 Electronic Theory

Based on the premise that the mucosal surface and the mucoadhesive material have different electronic structures, this theory suggests that an electrical double layer forms at the interface, resulting in attractive electrostatic forces.^{[1],[3],[4],[22]}

4.4 Adsorption Theory

This is the most widely accepted theory, involving secondary chemical bonds such as hydrogen bonding, van der Waals forces, and hydrophobic interactions between the polymer and the mucin.^{[1],[3],[4],[15],[19]}

4.5 Fracture Theory

Unlike other theories that focus on the formation of the bond, fracture theory analyzes the force required to separate two surfaces after adhesion has occurred. It relates the adhesive strength to the mechanical properties of the interface.^{[1],[4],[21],[22]}

Table 1: Comparative Analysis of Mucoadhesion Theories.

Theory	Principle Mechanism	Key Factors	Ref
Wetting	Surface spreading	Contact angle, spreading coefficient	[1], [13]
Diffusion	Chain entanglement	MW, chain mobility	[1], [4], [60]
Electronic	Electrostatic attraction	Surface charge, Zeta potential	[3], [21], [22]
Adsorption	Secondary bonding	Functional groups (-OH, -COOH)	[4], [19]
Fracture	Mechanical separation	Tensile strength, work of adhesion	[4], [23]

5. Factors Affecting Mucoadhesion

The efficiency of mucoadhesion is governed by polymer-related, environmental, and physiological factors.^{[5],[18]}

5.1 Polymer-Related Factors

- **Molecular Weight:** Generally, an optimal molecular weight is required; too low results in weak interpenetration, while too high may limit chain mobility.^{[18],[60]}
- **Concentration:** Higher polymer concentrations typically increase adhesive strength up to an optimum point.^{[18],[88]}
- **Flexibility:** Flexible chains allow better interpenetration.^{[18],[47]}
- **Swelling:** Necessary to expose adhesive sites but excessive swelling can lead to cohesive failure.^{[6],[15],[23]}

5.2 Environmental and Physiological Factors

- **pH:** Influences the ionization state of the polymer and the mucin, as well as the mucus rheology.^{[46],[51],[83]}
- **Mucus Turnover Rate:** Rapid turnover (e.g., in the respiratory tract) reduces the residence time of mucoadhesive systems.^[80]
- **Hydration:** Optimal hydration is essential for polymer swelling; however, over-hydration can lead to premature detachment.^{[9],[102]}

Table 2: Factors affecting Mucoadhesion.

Factor	Effect on Mucoadhesion	Ref
MW	Bell-shaped curve influence	[18], [60]
Charge	Increases (if opposite to mucin)	[46], [76]
pH	Variable based on ionization	[46], [104]
Hydration	Facilitates then hinders	[9], [102]
Turnover	Decreases residence time	[80]

6. Classification and Properties of Mucoadhesive Polymers

6.1 First-Generation Polymers

These are conventional mucoadhesive polymers that primarily utilize non-specific interactions like hydrogen bonding and electrostatic attraction.^[1]

- **Natural Polymers:** Chitosan, sodium alginate, pectin, and hyaluronic acid.^{[7],[9],[34],[43],[59]}
- **Synthetic Polymers:** Polyacrylic acid (Carbopol), HPMC, and PVA.^{[14],[26],[28],[32], [77]}

Table 3: Comparative Properties of First-Generation Polymers.

Polymer	Charge	Mucoadhesive Strength	Ref
Chitosan	Cationic	High	[7], [36]
Sodium Alginate	Anionic	Moderate	[50], [98]
Carbopol	Anionic	Very High	[14], [28]
HPMC	Non-ionic	Moderate	[14], [26]

6.2 Second-Generation Polymers

Advanced polymers have been developed to provide site-specific adhesion.^{[18],[30],[38]}

- Thiolated Polymers (Thiomers): Form covalent disulfide bonds with mucin.^{[1],[48],[57],[68]}
- Lectin-Mediated Systems: Targeted sugar binding.^{[18],[93]}
- Catechol-Functionalized Polymers: Mussel-inspired strong adhesion.^{[12],[38]}
- Stimuli-Responsive Polymers: Phase transitions in response to pH or temperature.^{[18],[74],[75]}

Table 4: Advanced/Second-Generation Polymers: Advantages and Applications.

Polymer Type	Advantage	Application	Ref
Thiomers	Covalent bonding	Oral, Ocular	[57], [68]
Lectins	High specificity	Cancer therapy	[18]
Boronic Acid	Sialic acid binding	Ocular, Vaginal	[56], [70]
Catechols	Wet adhesion	Oral cavity	[12], [38]

7. Evolution and Generations

- First Generation: Traditional cellulose derivatives and polyacrylic acids (1980s-1990s).^{[8],[15]}
- Second Generation: Thiomers, lectins, and nanoparticles (2000s-2010s).^{[57],[99]}
- Third Generation: Smart systems, 3D printing, and stimuli-responsive materials (2020-Present).^{[18],[45],[53]}

8. Mucoadhesive Dosage Forms and Formulation Strategies

- Tablets: Multi-layered for unidirectional release.^{[14],[29]}
- Films and Patches: Flexible, highly preferred for buccal delivery^{[9], [39], [84], [100].}
- Hydrogels: Ideal for ocular and vaginal delivery^{[74], [75], [101], [105].}
- Nanoparticles: Mucoadhesive or muco-penetrating^{[12], [67], [94].}

Table 5: Mucoadhesive Dosage Forms: Pros and Cons.

Dosage Form	Advantages	Disadvantages	Ref
Tablets	High drug loading	Bulky, irritation	[14], [29]
Films/Patches	Flexible, fast dissolution	Limited drug loading	[9], [39], [84]
Hydrogels	Sustained release	Mechanical weakness	[74], [101]
Nanoparticles	Targeted delivery	Complex synthesis	[12], [67]

9. Route-wise Pharmaceutical Applications

- Buccal: Bypasses first-pass metabolism^{[3], [39], [65]}.
- Nasal: Large surface area, nose-to-brain targeting^{[25], [54], [73], [80]}.
- Ocular: Counteracts tear drainage^{[27], [35], [36], [49], [58]}.
- GI: Gastroretentive systems^{[37], [41], [53], [89]}.
- Vaginal/Rectal: Local and systemic delivery^{[5], [31], [71], [105]}.

Table 6: Route-specific Physiological Barriers and Delivery Strategies.

Route	Main Barrier	Strategy	Ref
Buccal	Saliva wash-out	Unidirectional patches	[39], [65]
Nasal	Mucociliary clearance	Viscous gels/sprays	[25], [80]
Ocular	Tear turnover	In situ hydrogels	[35], [75]
GI	Acidic pH, motility	Floating systems	[37], [41]

10. Evaluation and Characterization

- In Vitro: Tensile strength (detachment force), shear stress, rheological synergism^{[1],[4],[51],[77],[86]}
- Ex Vivo: Retention on animal tissue samples^{[77], [79]}.
- In Vivo: Gamma scintigraphy, MRI tracking^{[1], [20]}.

Table 7: Evaluation Methods for Mucoadhesion.

Method	Parameter	Principle	Ref
Tensile Tester	Detachment Force	Mechanical pulling	[1], [77]
Viscometer	Rheological Synergism	Viscosity increase	[51], [86]
Scintigraphy	Residence Time	Radiotracking	[1]
AFM	Binding Force	Molecular interaction	[78]

11. Comparative Evidence and Quantitative Analysis

Table 8: Quantitative Experimental Comparison of Mucoadhesive Systems.

Formulation	Polymer	Detachment Force (mN)	Ref
Buccal Film	Chitosan/Alginate	12.5 ± 1.2	[50]
Buccal Patch	Carbopol 934P	25.4 ± 2.1	[100]
Ocular Gel	Thiolated HA	18.9 ± 0.8	[58], [68]
Nasal Spray	Iota-Carrageenan	8.4 ± 0.6	[64]

12. Nanotechnology in Mucoadhesive Drug Delivery

Mucoadhesive nanoparticles (e.g., chitosan-based) are trapped in the outer mucus layer.^{[12],[67]}

In contrast, mucus-penetrating particles (MPPs) use PEG or zwitterionic coatings to diffuse through the mucus to the epithelium.^{[33], [69], [70], [106].}

13. Recent Advances and Emerging Technologies (2020-2026)

- Thiomers Advancements: Pre-activated thiomers and thiolated cyclodextrins.^{[1],[48],[68],[103]}
- 3D Printing: Personalized mucoadhesive patches with complex profiles.^{[18],[45],[53]}
- Bio-inspired Designs: Catechol-modified (mussel-inspired) and sugar-based polymers.^{[12],[38],[55]}

Table 9: Recent Technological Innovations (2020-2026).

Innovation	Advantage	Ref
Thiomers	Covalent, long-term adhesion	[1], [57]
3D Printing	Personalized geometry	[18], [45]
Catechol Grafting	Strong wet adhesion	[12], [38]
Smart Micelles	Triggered release	[74], [75]

14. Therapeutic and Clinical Applications

- Cancer: Local doxorubicin delivery in oral cavity carcinoma.^{[12],[97]}
- Inflammatory Disease: Sustained localized effect in chronic mucosal diseases.^[16]
- Pediatrics/Geriatrics: Films and wafers for easier administration.^[22]

15. Marketed Products and Translational Status

Table 10: Marketed Mucoadhesive Pharmaceutical Products.

Product	Drug	Route	Ref
Buccastem®	Prochlorperazine	Buccal	[14]
Striant®	Testosterone	Buccal	[10]
Crinone®	Progesterone	Vaginal	[10]
Arestin®	Minocycline	Periodontal	[24]

16. Safety, Toxicity and Biocompatibility

- Natural Polymers: Generally safe and biodegradable.^{[7],[9],[58]}
- Synthetic Excipients: Require rigorous toxicity testing for irritation and systemic absorption.^{[10],[14],[19],[20]}
- Challenges: Potential for local irritation or interfering with mucus protection.^{[22],[42]}

17. Regulatory and Manufacturing Considerations

- Manufacturing: Scale-up challenges, batch-to-batch variation, and stability.^{[9],[12],[40]}
- Regulatory: Lack of standardized monographs for novel polymers and functionalized thiomers.^{[9],[19],[20]}

Table 11: Translational Challenges and Potential Solutions.

Challenge	Potential Solution	Ref
Standardization	Developing monographs	[9]
Mucus Variability	Stimuli-responsive systems	[12], [18]
Manufacturing Cost	Simplified fabrication (3D printing)	[12], [45]

18. Critical Discussion

A persistent translational gap exists between increasingly sophisticated polymer designs and their clinical adoptability.^[12] While thiomers show remarkable adhesion *in vitro*, the dynamic human mucosal environment remains a challenge.^{[2], [22]} The emergence of mucus-penetrating systems further demonstrates that maximal adhesion is not universally desirable; the optimal strategy depends on the therapeutic target, mucus turnover, and required epithelial access.^{[69],[106]}

19. Current Challenges and Research Gaps

- Molecular Level: Lack of definitive models for mucin-polymer interactions.^{[2],[59]}
- In Vitro Models: Need for better human-mimetic systems.^{[52],[90]}
- Safety Data: Limited information on long-term effects of repeated applications.^[22]

20. Future Perspectives

Future trends include "smart" mucoadhesive patches with digital health monitoring, bio-inspired adhesives for wet environments, and dual-action (adhesion + penetration) systems.^{[18],[38],[45],[55],[91],[103]}

21. CONCLUSION

Mucoadhesive drug delivery systems have progressed from conventional polymeric platforms to multifunctional systems capable of prolonged residence, controlled release, epithelial targeting, and stimulus-responsive behavior. However, clinical translation remains constrained by variability in mucus biology, limited standardization of mucoadhesion testing, scale-up challenges, and incomplete long-term safety evidence. Future progress will depend on clinically relevant models, harmonized characterization methods, quality-by-design

manufacturing, and direct comparison of mucoadhesive and mucus-penetrating strategies.

Figure Concepts and Legends

Figure 1: Mucin Glycoprotein Structure.^{[62],[72],[81]}

Figure 2: Two-Stage Mucoadhesion Mechanism.^{[6],[15],[17]}

Figure 3: Biophysical Theories of Adhesion.^{[1],[4],[13]}

Figure 4: Evolution of MDDS Generations.^{[1],[18],[45]}

Figure 5: Major Routes for MDDS.^{[5],[18],[95]}

Figure 6: Thiol-Disulfide Exchange Mechanism.^{[1],[57],[68]}

Figure 7: Mucoadhesive vs. Mucus-Penetrating NPs.^{[69],[82],[106]}

REFERENCES

1. Vigneshwaran M, Madhan V, Pradeep A, Hemanth G. Mucoadhesive Drug Delivery Systems: Principles, Polymers, Pharmaceutical Applications, and Recent Advances. Zenodo, 2026. DOI: 10.5281/zenodo.18138141.
2. M. K., D. M., V. P. A review on: mucoadhesive drug delivery systems. Journal of innovations in applied pharmaceutical sciences, 2022. DOI: 10.37022/jiaps.v7i1.278.
3. Mucoadhesive Buccal Drug Delivery: A Review. Zenodo, 2024. DOI: 10.5281/zenodo.14305297.
4. Patil GC, Jain AS, Patil DR et al. An Examination of the Mucoadhesive Drug Distribution System. Zenodo, 2024. DOI: 10.5281/zenodo.11379737.
5. Alawdi S, Solanki AB. Mucoadhesive Drug Delivery Systems: A Review of Recent Developments. JSRMBS, 2021. DOI: 10.47631/JSRMBS.V2I1.213.
6. Patil P, Deshmukh G, Palve V et al. An Overview: Mucoadhesive Buccal Drug Delivery System. Zenodo, 2025. DOI: 10.5281/zenodo.15534411.
7. Devi S, Bhatia M, Grewal S. Polymers for Mucoadhesive Drug Delivery Systems. APS. 2021. DOI: 10.23893/1307-2080.APS.05919.
8. Patil ND, Saudagar RB, Sapkal RG. A review - mucoadhesive buccal drug delivery systems. 2015.
9. Khade A, Sabale V, Gadge G et al. An overview on natural polymer based mucoadhesive buccal films for controlled drug delivery. IRJPS. 2019. DOI: 10.21276/IRJPS.2019.6.1.7.
10. Tangri P, Jawla S, Jakhmola V et al. Highlights of Mucoadhesive Drug Delivery Systems: A Review. IGJPS. 2017. DOI: 10.35652/IGJPS.2017.111.
11. Kulkarni R, Fanse S, Burgess DJ. Mucoadhesive drug delivery systems: a promising non-

- invasive approach to bioavailability enhancement. Part I: biophysical considerations. Expert Opinion on Drug Delivery, 2023. DOI: 10.1080/17425247.2023.2181331.
12. Pandey M, Choudhury H, Ying JNS et al. Mucoadhesive Nanocarriers as a Promising Strategy to Enhance Intracellular Delivery against Oral Cavity Carcinoma. *Pharmaceutics*, 2022. DOI: 10.3390/pharmaceutics14040795.
 13. Enhancing drug bioavailability through mucoadhesive technologies: A comprehensive review of delivery systems, 2025. DOI: 10.1007/s44174-025-00405-2.
 14. Puri V, Sharma A, Maman P et al. Overview of mucoadhesive biopolymers for buccal drug delivery systems. *International Journal of Applied Pharmaceutics*, 2019. DOI: 10.22159/IJAP.2019V11I6.35438.
 15. Mucoadhesive polymeric platform for drug delivery; a comprehensive review, 2014. DOI: 10.2174/1567201811666140924124722.
 16. Mucoadhesive drug delivery systems for oral chronic inflammatory mucosal diseases. The future is already present. A systematic review. DOI: 10.1111/odi.70042.
 17. Kumar PV, Saravanakumar K, Nagaveni P et al. Novel review on mucoadhesive drug delivery system. *International Journal of Research in Pharmaceutical Sciences*, 2016.
 18. Kasani J. A review on Applications of Mucoadhesive Drug Delivery Systems. *Journal of Pharma Insights and Research*. 2025. DOI: 10.69613/zkrcve55.
 19. Baste NS, Shahare SH, Mundada AS. Comprehensive Insights into Mucoadhesive Drug Delivery Systems, 2024. DOI: 10.2174/9789815274165124010010.
 20. Kurakual S, Singampalli M, Putta S. Bio-enhancement in mucoadhesive drug delivery systems: A review. *GSC biological and pharmaceutical sciences*, 2025. DOI: 10.30574/gscbps.2025.33.3.0490.
 21. Review: A mucoadhesive drug delivery system. *Zenodo*, 2023. DOI: 10.5281/zenodo.10435593.
 22. Rai A, Rawat S, Rathi R et al. Mucoadhesive Drug Delivery Systems for Pediatric and Geriatric Patients. *FABAD journal of pharmaceutical sciences*, 2023. DOI: 10.55262/fabadeczacilik.1279777.
 23. Satpute KL, Jadhav M, Panchal A. Oral mucoadhesive drug delivery systems: a review, 2020.
 24. Rath R, Tevatia S, Rath A et al. Mucoadhesive systems in dentistry: A review. *IJDR*. 2016. DOI: 10.14419/IJDR.V4I2.6283.
 25. Anand U, Feridooni T, Agu RU. Novel Mucoadhesive Polymers for Nasal Drug Delivery, 2012. DOI: 10.5772/52560.

26. Hari Hara Nadh TV, Ramana MV, Ramarao N. An Overview on Mucoadhesive Polymers for Buccal Drug Delivery. *IJPSRR*, 2021. DOI: 10.47583/IJPSRR.2021.V67I01.029.
27. Desai N, Colley H, Krishna Y et al. Mucoadhesive nanofibers for ocular drug delivery: mechanisms, design strategies, and applications. *Drug Delivery and Translational Research*, 2025. DOI: 10.1007/s13346-025-01894-w.
28. Shaikh TA, Shinkar DM, Saudagar RB. Review: Polymers Used in the Mucoadhesive Drug Delivery System. *International Journal of Pharma Research & Review*, 2016.
29. Nagaveni P, Sirisha S, Rao CA. A complete review on Mucoadhesive Buccal Tablets. *Research Journal of Pharmaceutical Dosage Forms and Technology*, 2021. DOI: 10.52711/0975-4377.2021.00022.
30. Brannigan RP, Khutoryanskiy VV. Progress and Current Trends in the Synthesis of Novel Polymers with Enhanced Mucoadhesive Properties. *Macromolecular Bioscience*, 2019. DOI: 10.1002/MABI.201900194.
31. Ojha A. An exhaustive statistic on current mucoadhesive intravaginal drug delivery methodologies. *UJPR*, 2018. DOI: 10.22270/UJPR.V2I6.RW3.
32. Verma S. Polymers in designing the mucoadhesive films: A comprehensive review. *International Journal of Green Pharmacy*, 2018. DOI: 10.22377/IJGP.V12I02.1783.
33. Watchorn JD, Clasky AJ, Prakash G et al. Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier. *ACS Biomaterials Science & Engineering*, 2022. DOI: 10.1021/acsbiomaterials.2c00047.
34. Brooks AE. The Potential of Silk and Silk-Like Proteins as Natural Mucoadhesive Biopolymers for Controlled Drug Delivery. *Frontiers in Chemistry*, 2015. DOI: 10.3389/FCHEM.2015.00065.
35. Račić A, Krajišnik D. Biopolymers in Mucoadhesive Eye Drops for Treatment of Dry Eye and Allergic Conditions: Application and Perspectives. *Pharmaceutics*, 2023. DOI: 10.3390/pharmaceutics15020470.
36. Zamboulis A, Nanaki S, Michailidou G et al. Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments. *Polymers*, 2020. DOI: 10.3390/POLYM12071519.
37. Ebraheem AS, Elfar N, Yasser M. Gastroretentive Drug Delivery Systems: A Summarized Overview, 2023. DOI: 10.21608/odr.2023.209174.1027.
38. Jawadi Z, Yang C, Haidar ZS et al. Bio-Inspired Muco-Adhesive Polymers for Drug Delivery Applications. *Polymers*, 2022. DOI: 10.3390/polym14245459.
39. Jacob S, Nair AB, Boddu SHS et al. An Updated Overview of the Emerging Role of

- Patch and Film-Based Buccal Delivery Systems. *Pharmaceutics*, 2021. DOI: 10.3390/PHARMACEUTICS13081206.
40. Pérez-González GL, Villarreal-Gómez LJ, Serrano-Medina A et al. Mucoadhesive electrospun nanofibers for drug delivery systems: applications of polymers and the parameters' roles. *International Journal of Nanomedicine*, 2019. DOI: 10.2147/IJN.S193328.
41. Arun JK, Pattanayak D, Shrivastava B et al. A systemic review on Floating Mucoadhesive drug Delivery system and its Present Scenario. *Research Journal of Pharmacy and Technology*, 2020. DOI: 10.5958/0974-360X.2020.00795.7.
42. Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers, 2023. DOI: 10.1016/j.ijpharm.2023.122661.
43. Pelin IM, Suflet DM. Mucoadhesive buccal drug delivery systems containing polysaccharides. *Cellulose Chemistry and Technology*, 2020. DOI: 10.35812/CELLULOSECHEMTECHNOL.2020.54.86.
44. Fröhlich E. Non-cellular layers of the respiratory tract: Protection against Pathogens and Target for Drug Delivery. *Pharmaceutics*, 2022. DOI: 10.3390/pharmaceutics14050992.
45. Bayer IS. Recent Advances in Mucoadhesive Interface Materials, Mucoadhesion Characterization, and Technologies. *Advanced Materials Interfaces*, 2022. DOI: 10.1002/admi.202200211.
46. An overview of gastrointestinal mucus rheology under different pH conditions and introduction to pH-dependent rheological interactions with PLGA and chitosan nanoparticles, 2020. DOI: 10.1016/j.ejpb.2020.12.013.
47. Mechanistic Influence of Polymer Species, Molecular Weight, and Functionalization on Mucin-Polymer Binding Interactions, 2022. DOI: 10.1021/acsapm.2c01220.s001.
48. Marwaha TK, Madgulkar AR, Bhalekar MR et al. Tailoring the properties of chitosan by grafting with 2-mercaptobenzoic acid to improve mucoadhesion: in silico studies, synthesis and characterization. *Progress in Biomaterials*, 2022. DOI: 10.1007/s40204-022-00201-x.
49. Kim M, Jung MY, Lee D et al. How to Fabricate Hyaluronic Acid for Ocular Drug Delivery. *Pharmaceutics*, 2024. DOI: 10.3390/pharmaceutics16121604.
50. Pamlényi K. Development of buccal mucoadhesive polymer films with sodium alginate and cetirizine dihydrochloride in allergy therapy, 2023. DOI: 10.14232/phd.11618.
51. Mucin-polysaccharide interactions: A rheological approach to evaluate the effect of pH on the mucoadhesive properties, 2020. DOI: 10.1016/j.ijbiomac.2020.01.235.

52. Models to evaluate the barrier properties of mucus during drug diffusion, 2021. DOI: 10.1016/j.ijpharm.2021.120415.
53. Oral sustained release expandable dosage forms: innovations, challenges, and future directions, 2025. DOI: 10.1080/09205063.2025.2528935.
54. Kapoor D, Patel M, Vyas RB et al. Site specific drug delivery through nasal route using bioadhesive polymers. *Journal of Drug Delivery and Therapeutics*, 2015. DOI: 10.22270/JDDT.V5I1.873.
55. Ejaz S, Hogg BV, Hristov DR et al. Add Sugar to Chitosan: Mucoadhesion and In Vitro Intestinal Permeability of Mannosylated Chitosan Nanocarriers. *Pharmaceutics*, 2022. DOI: 10.3390/pharmaceutics14040830.
56. Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery, 2016. DOI: 10.1021/acs.biomac.6b00054.
57. Mucus permeating thiomers nanoparticles, 2015. DOI: 10.1016/j.ejpb.2015.01.004.
58. Guarise C, Acquasaliente L, Pasut G et al. The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model. *Journal of The Mechanical Behavior of Biomedical Materials*, 2023. DOI: 10.1016/j.jmbbm.2023.105908.
59. Biophysical Analysis of the Molecular Interactions between Polysaccharides and Mucin. 2016. DOI: 10.1021/bm501832y.s001.
60. Watchorn JD, Stuart SDF, Burns DC et al. Mechanistic Influence of Polymer Species, Molecular Weight, and Functionalization on Mucin-Polymer Binding Interactions. *ACS applied polymer materials*, 2022. DOI: 10.1021/acsapm.2c01220.
61. Ruiz-Pulido G, Quintanar-Guerrero D, Serrano-Mora LE et al. Triborheological Analysis of Reconstituted Gastrointestinal Mucus/Chitosan:TPP Nanoparticles System to Study Mucoadhesion Phenomenon under Different pH Conditions. *Polymers*, 2022. DOI: 10.3390/polym14224978.
62. Demouveau B, Gouyer V, Magnien M et al. La structure des mucines conditionne les propriétés viscoélastiques des gels de mucus. *M S-medicine Sciences*, 2018. DOI: 10.1051/MEDSCI/2018206.
63. The role of mucus on drug transport and its potential to affect therapeutic outcomes, 2017. DOI: 10.1016/j.addr.2017.10.009.
64. Robinson TE, Moakes RJA, Grover LM. Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2., 2021. DOI: 10.3389/FMEDT.2021.687681.
65. Di Prima G. Buccal Thin Films as Potent Permeation Enhancers for Cytisine Transbuccal

- Delivery. *Membranes*, 2022. DOI: 10.3390/membranes12111169.
66. Time-dependent mucoadhesion of conjugated bioadhesive polymers, 2018. DOI: 10.1016/j.colsurfb.2018.10.011.
67. Mucoadhesive and mucopenetrating chitosan nanoparticles for glycopeptide antibiotic administration, 2021. DOI: 10.1016/j.ijpharm.2021.120874.
68. Grassiri B, Knoll P, Fabiano A et al. Thiolated Hydroxypropyl-beta-cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery. *International Journal of Molecular Sciences*, 2022. DOI: 10.3390/ijms23052612.
69. Nanoparticles across mucosal barriers: Differentiating mucoadhesion from mucopenetration using single particle tracking, 2025. DOI: 10.1016/j.jconrel.2025.114268.
70. Cureno Hernandez KE, Herrera Alonso M, Hill M et al. Engineering zwitterionic and boronic acid-based nanomaterials to overcome mucosal barriers, 2025. DOI: 10.25675/3.025692.
71. Novel Mucoadhesive Wafers for Treating Local Vaginal Infections, 2022. DOI: 10.3390/biomedicines10123036.
72. Wagner CE, Wheeler KM, Ribbeck K. Mucins and Their Role in Shaping the Functions of Mucus Barriers. *Annual Review of Cell and Developmental Biology*, 2018. DOI: 10.1146/ANNUREV-CELLBIO-100617-062818.
73. Methyl-cellulose powder for prevention and management of nasal symptoms, 2017. DOI: 10.1080/17476348.2017.1375408.
74. Sepulveda AF, Silva JBD, Bruschi ML et al. Influence of structural organization on mucoadhesive properties of poloxamer-hyaluronic acid-based micelles and hydrogels: from molecular modelling to biointerfaces interactions. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 2024. DOI: 10.1016/j.colsurfa.2024.134527.
75. Hamed R, Abu Kwiak AD, Al-Adhami Y et al. Microemulsions as Lipid Nanosystems Loaded into Thermoresponsive In Situ Microgels for Local Ocular Delivery of Prednisolone. *Pharmaceutics*, 2022. DOI: 10.3390/pharmaceutics14091975.
76. Porfiryeva NN, Zlotver I, Sosnik A. Combined effect of size and charge on the interaction of Na-noparticles with Mucus-Mimicking Mucin Hydrogels, 2025. DOI: 10.26434/chemrxiv-2025-p3hqt.
77. Müller L, Rosenbaum CG, Krause J et al. Characterization of an In Vitro/Ex Vivo Mucoadhesiveness Measurement Method of PVA Films. *Polymers*, 2022. DOI: 10.3390/polym14235146.

78. Schlatterer R, Marczyński M, Hermann BA et al. Unfolding of von Willebrand Factor Type D Like Domains Promotes Mucin Adhesion. *Nano Letters*, 2025. DOI: 10.1021/acs.nanolett.4c03088.
79. Winter C, Hartl S, Kolb D et al. Investigations to Evaluate Gastric Mucoadhesion of an Organic Product to Ameliorate Gastritis. *Pharmaceutics*, 2020. DOI: 10.3390/PHARMACEUTICS12040331.
80. Trenkel M, Scherließ R. Nasal Powder Formulations: In-Vitro Characterisation of the Impact of Powders on Nasal Residence Time and Sensory Effects. *Pharmaceutics*, 2021. DOI: 10.3390/PHARMACEUTICS13030385.
81. Curnutt A, Smith K, Darrow E et al. Chemical and Microstructural Characterization of pH and [Ca²⁺] Dependent Sol-Gel Transitions in Mucin Biopolymer. *Scientific Reports*, 2020. DOI: 10.1038/S41598-020-65392-4.
82. Inchaurreaga-Casadamon L. Mucus-penetrating nanoparticles for the oral delivery of insulin, 2017.
83. Caicedo J, Perilla JE. Effect of pH on the rheological response of reconstituted gastric mucin, 2015.
84. More A, Diwate S, Deshmukh A. Mucoadhesive Buccal Film: An Emerging Platform for Controlled Drug Delivery Systems. *Zenodo*, 2026. DOI: 10.5281/zenodo.18213779.
85. Porwal A, Pathak K. Bioadhesion, 2023. DOI: 10.1002/9781394209897.ch4.
86. Rulff H, Schmidt RF, Wei LF et al. A comprehensive characterization of the viscoelastic properties of Bovine Submaxillary Mucin (BSM) and the effect of additives. *bioRxiv*, 2024. DOI: 10.1101/2024.01.17.576019.
87. Enhancing therapeutic efficacy with mucoadhesive drug delivery. *Zenodo*, 2023. DOI: 10.5281/zenodo.10324894.
88. Chatterjee B, Amalina N, Sengupta P et al. Mucoadhesive Polymers and Their Mode of Action: A Recent Update. *Journal of applied pharmaceutical science*, 2017. DOI: 10.7324/japs.2017.70533.
89. Subramanian DA, Langer R, Traverso G. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. *Journal of Nanobiotechnology*, 2022. DOI: 10.1186/s12951-022-01539-x.
90. Pacheco DP, Butnarasu C, Vangosa FB et al. Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery. *Journal of Materials Chemistry B*, 2019. DOI: 10.1039/C9TB00957D.
91. Edwards SE, Flynn S, Hobson JJ et al. Mucus-responsive functionalized emulsions:

- design, synthesis and study of novel branched polymers as functional emulsifiers. RSC Advances, 2020. DOI: 10.1039/D0RA05820C.
92. Chauhan V, Agrawal A, Singh U. A comprehensive review on Mucoadhesive Drug Delivery. Journal of Drug Delivery and Therapeutics, 2022. DOI: 10.22270/jddt.v12i4-s.5610.
93. Mansuri S, Kesharwani P, Kesharwani P et al. Mucoadhesion: A promising approach in drug delivery system. Reactive & Functional Polymers, 2016. DOI: 10.1016/J.REACTFUNCTPOLYM.2016.01.011.
94. Sabareesh M, Suma PF, Ravi M et al. Nanoparticles Loaded Mucoadhesive Buccal Patches - Review. Journal of pharmaceutical research international, 2022. DOI: 10.9734/jpri/2022/v34i46b36388.
95. Mangla B, Javed S, Sultan MH et al. Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit. Frontiers in Pharmacology, 2022. DOI: 10.3389/fphar.2021.757761.
96. Charakterisierung der strukturellen Eigenschaften von Mukusmodellsystemen und menschlichem Mukus im gesunden und erkrankten Zustand, 2025. DOI: 10.14279/depositonce-22512.
97. Afrin H, Bai RG, Kumar R et al. Oral delivery of RNAi for cancer therapy. Cancer and Metastasis Reviews. 2023. DOI: 10.1007/s10555-023-10099-x.
98. Perkasa DP, Arozal W, Sharif M. Potentials of Alginates as Capping Agent for Oral Colon Delivery of Radiosynthesized Silver Nanoparticles: A Review. Atom Indonesia, 2022. DOI: 10.17146/aij.2022.1082.
99. Irons BK, Robinson JR. Bioadhesives in Drug Delivery. 2005.
100. Meher JG, Meher JG, Tarai M et al. Cellulose Buccoadhesive Film Bearing Glimepiride: Physicomechanical Characterization and Biophysics of Buccoadhesion. Aaps Pharmscitech, 2016. DOI: 10.1208/S12249-015-0419-5.
101. Pharmaceutical chitosan hydrogels: A review on its design and applications, 2024. DOI: 10.1016/j.ijbiomac.2024.135775.
102. Dehydration affects drug transport over nasal mucosa, 2019. DOI: 10.1080/10717544.2019.1650848.
103. Microwave-assisted, sulfhydryl-modified beta-cyclodextrin-silymarin inclusion complex: A diverse approach to improve oral drug bioavailability via enhanced mucoadhesion and permeation, 2024. DOI: 10.1016/j.carbpol.2024.122880.
104. Caicedo JA, Perilla Perilla JE. Effect of pH on the rheological response of reconstituted

- gastric mucin. Revista Ingenieria E Investigacion, 2015. DOI: 10.15446/ING.INVESTIG.V35N2.50019.
105. Rençber S, Karavana SY, Şenyiğit ZA et al. Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation. Pharmaceutical Development and Technology, 2017. DOI: 10.3109/10837450.2016.1163385.
106. Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials. 2017. DOI: 10.1016/j.addr.2017.07.015.

Appendix: Abbreviation List

- MDDS: Mucoadhesive Drug Delivery Systems
- GI: Gastrointestinal
- BSM: Bovine Submaxillary Mucin
- PEG: Polyethylene Glycol
- CMC: Carboxymethyl Cellulose
- HPMC: Hydroxypropyl Methylcellulose
- PVA: Polyvinyl Alcohol
- GIT: Gastrointestinal Tract
- PVP: Polyvinylpyrrolidone
- HEC: Hydroxyethyl Cellulose
- PAA: Poly(acrylic acid)